Browsing School of Engineering and Materials Science by Author "van de Donk, NWCJ"
Now showing items 1-4 of 4
-
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Naik, J; Themeli, M; de Jong-Korlaar, R; Ruiter, RWJ; Poddighe, PJ; Yuan, H; de Bruijn, JD; Ossenkoppele, GJ; Zweegman, S; Smit, L (Ferrata Storti Foundation, 2019-03)Acute leukemia is a clonal expansion of malignant hematopoietic cells leading to impaired production of normal blood cells in the bone marrow (BM). Acute leukemia can be classified, according to the lineage involved, into ... -
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells
Drent, E; Poels, R; Ruiter, R; van de Donk, NWCJ; Zweegman, S; Yuan, H; de Bruijn, J; Sadelain, M; Lokhorst, HM; Groen, RWJ (2019-07-01) -
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Drent, E; Groen, RWJ; Noort, WA; Themeli, M; van Bueren, JJL; Parren, PWHI; Kuball, J; Sebestyen, Z; Yuan, H; de Bruijn, J (2016-05) -
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.
de Haart, SJ; Holthof, L; Noort, WA; Minnema, MC; Emmelot, ME; Aarts-Riemens, T; Doshi, P; Sasser, K; Yuan, H; de Bruijn, J (2016-08)